This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): AC-262271
Description: AC-262271 targets a subtype of the muscarinic receptor that Acadia believes controls intraocular pressure. The drug has produced a long lasting reduction of intraocular pressure in primate models of glaucoma.
Acadia and Allergan
In July 1999, Acadia entered into a collaboration agreement with Allergan to discover, develop and commercialize selective muscarinic drugs for the treatment of glaucoma based on Acadias compounds. Under this agreement, Acadia provided their chemistry and discovery expertise to enable Allergan to select a compound in November 2003 for development. Acadia granted Allergan exclusive worldwide rights to commercialize products based on this compound for the treatment of ocular disease. As of December 31, 2006, Acadia had received an aggregate of $8.8 million in payments under the agreement, consisting of upfront fees, research funding and milestone payments. Acadia is also eligible to receive additional milestone payments of up to approximately $15.2 million, and would receive royalties on future product sales worldwide, if any. Allergan may terminate this agreement upon 90 days notice. However, if terminated, Allergans rights to the selected compound would...See full deal structure in Biomedtracker
Partners: Acadia Pharmaceuticals, Inc.
Additional information available to subscribers only: